Skip to main content
SpringerLink
Log in

Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis

Focus on the Soluble TNF Receptor p75 Fusion Protein, Etanercept

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Tumour necrosis factor (TNF) is the dominant mediator of the cytokine cascade that causes inflammation and joint detruction in rheumatoid arthritis. A new class of agents under investigation, the biological TNF inhibitors, inhibit the activity of TNF. Recombinant human TNF receptor p75 Fc fusion protein (TNFR: Fc; etanercept) blocks the activity of the cytokine TNF. The preclinical and pivotal trials evaluating etanercept in rheumatoid arthritis are reviewed in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754–9

    Article  PubMed  CAS  Google Scholar 

  2. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125–32

    Article  PubMed  CAS  Google Scholar 

  3. Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041–5

    Article  PubMed  CAS  Google Scholar 

  4. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on Superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387–91

    Google Scholar 

  5. MacNaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, colla-genase and then natural inhibitor, TTMP, in rheumatoid synovial fibroblasts. Matrix 1992; 1 Suppl.: 198–9

    PubMed  CAS  Google Scholar 

  6. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TTMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immuol 1993; 94: 145–9

    Article  CAS  Google Scholar 

  7. Moser RB, Schleiffenbaum B, Groscurth P, et al. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989; 83: 444–55

    Article  PubMed  CAS  Google Scholar 

  8. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effects of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; II: 244–7

    Article  Google Scholar 

  9. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis-alpha. Eur J Immunol 1991; 21: 2575–9

    Article  PubMed  CAS  Google Scholar 

  10. Banner DW, D’Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431–45

    Article  PubMed  CAS  Google Scholar 

  11. Seckinger P, Zhang J, Hauptmann B, et al. Characterization of a tumor necrosis factor a (TNF) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188–92

    Article  PubMed  CAS  Google Scholar 

  12. Engelmann H, Aderka D, Rubinstein M, et al. Atumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974–80

    PubMed  CAS  Google Scholar 

  13. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270–5

    Article  PubMed  CAS  Google Scholar 

  14. Deleuran BW, Chu CQ, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992; 35: 1170–8

    Article  PubMed  CAS  Google Scholar 

  15. Pennica D, Lam VT, Mize NK, et al. Biochemical properties of the 75Kda tumor necrosis factor receptor: characterization of the ligand binding, internalization, and receptor phosphorylation. J Biol Chem 1992; 267: 21172–8

    PubMed  CAS  Google Scholar 

  16. Westacott CI, Atkins RM, Dieppe PA, et al. Tumor necrosis factor-α receptor expression on chondrocytes isolated from human articular cartilage. J Rhematol 1994; 21: 1710–5

    CAS  Google Scholar 

  17. Barrera P, Boerbooms AM, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070–9

    Article  PubMed  CAS  Google Scholar 

  18. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160–9

    Article  PubMed  CAS  Google Scholar 

  19. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485–9

    Article  PubMed  CAS  Google Scholar 

  20. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111–20

    Article  PubMed  CAS  Google Scholar 

  21. Heilig B, Fiehn C, Brockhaus M, et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993; 13: 321–8

    Article  PubMed  CAS  Google Scholar 

  22. Andus T, Gross V, Holstege A, et al. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology 1992; 16: 749–55

    Article  PubMed  CAS  Google Scholar 

  23. Austgulen R, Liabakk NB, Lien E, et al. Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from new-borns. Pediatr Res 1993; 33: 82–7

    Article  PubMed  CAS  Google Scholar 

  24. Baumann P, Romero R, Berry S, et al. Evidence of participation of the soluble tumor necrosis factor receptor I in the host response to intrauterine infection in preterm labor. Am J Reprod Immunol 1993; 30: 184–93

    PubMed  CAS  Google Scholar 

  25. Bemelmans MHA, Grève JWM, Gouma DJ, et al. Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality. Gut 1996; 38: 447–53

    Article  PubMed  CAS  Google Scholar 

  26. Brockhaus M, Bar-Khayim Y, Gurwicz S, et al. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663–7

    Article  PubMed  CAS  Google Scholar 

  27. Crëange A, Bëlec L, Clair B, et al. Circulating rumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barrë syndrome. J Neurol 1996; 68: 95–9

    Google Scholar 

  28. Digel W, Porzsolt F, Schmid M, et al. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992; 89: 1690–3

    Article  PubMed  CAS  Google Scholar 

  29. Elsasser-Beile U, Gallati H, Weber W, et al. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumor Biol 1994; 15: 17–24

    Article  CAS  Google Scholar 

  30. Engel A, Kern P, Kern WV. Levels of cytokines and cytokine inhibitors in the neutropenic patients with α-hemolytic streptococcus shock syndrome. Clin Infect Dis 1996; 23: 785–9

    Article  PubMed  CAS  Google Scholar 

  31. Froon AH, Bemelmans MH, Grève JW, et al. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803–9

    Article  PubMed  CAS  Google Scholar 

  32. Furukawa S, Masubara T, Umezawa Y, et al. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. Pediatrics 1994; 124: 721–5

    Article  CAS  Google Scholar 

  33. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlated with disease activity. J Rheumatol 1997; 24: 303–8

    PubMed  CAS  Google Scholar 

  34. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992; 76: 20–3

    PubMed  CAS  Google Scholar 

  35. Hino T, Nakamura H, Shibata Y, et al. Elevated levels of type II soluble tumor necrosis factor receptors in the broncho-alveolar lavage fluids of patients with sarcoidosis. Lung 1997; 175: 187–93

    Article  PubMed  CAS  Google Scholar 

  36. Ichiyama T, Hayashi T, Nishikawa M, et al. Cerebrospinal fluid levels of soluble tumour necrosis factor receptor in acute encephalitis. J Neurol 1996; 243: 457–60

    Article  PubMed  CAS  Google Scholar 

  37. Kobayashi H, Fukata J, Murakami N, et al. Tumor necrosis factor receptors in the pituitary cells. Brain Res 1997; 758: 45–50

    Article  PubMed  CAS  Google Scholar 

  38. Kraus T, Mehrabi A, Arnold J, et al. Evaluation of soluble tumor necrosis factor receptors with orthotopic liver transplantation. Transplant Proc 1992; 24: 2539–41

    PubMed  CAS  Google Scholar 

  39. Kupfermine MJ, Peaceman AM, Aderka D, et al. Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. Obstet Gynecol 1996; 88: 420–7

    Article  Google Scholar 

  40. Lucas R, Lou J, Morel DR, et al. TNF receptors in the micro-vascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol 1997; 61: 551–8

    PubMed  CAS  Google Scholar 

  41. Messer J, Eyer D, Donato L, et al. Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr 1996; 129: 574–80

    Google Scholar 

  42. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1RNA and the clinical outcome. AIDS 1996; 10: F45–50

    Article  PubMed  CAS  Google Scholar 

  43. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992; 90: 533–6

    Article  PubMed  CAS  Google Scholar 

  44. Tsukada N, Matsuda M, Miyagi K, et al. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993; 43: 2679–82

    Article  PubMed  CAS  Google Scholar 

  45. Ward RA, Gordan L. Soluble tumor necrosis factor receptors are increased in hemodialysis patients. ASAIO J 1993; 39: M782–M6

    Article  PubMed  CAS  Google Scholar 

  46. Warzacha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lym-phoma patients. J Clin Oncol 1997; 15: 499–508

    Google Scholar 

  47. Yoshida S, Hashimoto S, Nakayama T, et al. Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma. Clin Exp Immunol 1996; 106: 73–8

    Article  PubMed  CAS  Google Scholar 

  48. Zangerle R, Gallati H, Sarcletti M, et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J AIDS 1994; 7: 79–85

    CAS  Google Scholar 

  49. Pennica D, Lam VT, Mize NK, et al. Biochemical properties of the 75-kDa tumor necrosis factor receptor: characterization of ligand binding, internalization, and receptor phosphorylation. J Biochem 1992; 267: 21172–8

    CAS  Google Scholar 

  50. Tartaglia LA, Weber RF, Figari IS, et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292–6

    Article  PubMed  CAS  Google Scholar 

  51. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40: 393–409

    Article  Google Scholar 

  52. Ferrante A, Hauptmann B, Seckinger P, et al. Inhibition of tumour necrosis factor alpha (TNF-α)-induced neutrophil respiratory burst by a TNF inhibitor. Immunology 1991; 72: 440–2

    PubMed  CAS  Google Scholar 

  53. Tilg H, Shapiro L, Atkins MB, et al. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 1993; 151: 3299–307

    PubMed  CAS  Google Scholar 

  54. Cope AP, Gibbons DL, Aderke D, et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; up-regulation of p55 and p75 TNF-R on synovial joint mononuclear cells. Cytokine 1993; 5: 205–12

    Article  PubMed  CAS  Google Scholar 

  55. Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994; 37: 232–5

    Article  PubMed  CAS  Google Scholar 

  56. Gatanaga T, Hwang CD, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781–4

    Article  PubMed  CAS  Google Scholar 

  57. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31

    PubMed  CAS  Google Scholar 

  58. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci 1992; 89: 9784–8

    Article  PubMed  CAS  Google Scholar 

  59. Williams RO, Mason LJ, Feldmann M, et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Nat Acad Sci USA 1994; 91: 2762–6

    Article  PubMed  CAS  Google Scholar 

  60. Williams RO, Chrayeb J, Feldman M, et al. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD-4. Immunology 1995; 84: 433–9

    PubMed  CAS  Google Scholar 

  61. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 11: 6602–7

    Google Scholar 

  62. Piguet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510–4

    PubMed  CAS  Google Scholar 

  63. Joosten LAB, Helsen MMA, van de Loo FAJ, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797–809

    Article  PubMed  CAS  Google Scholar 

  64. van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164–72

    Article  PubMed  Google Scholar 

  65. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 1993; 36: 1681–90

    Article  Google Scholar 

  66. Elliott MJ, Maini RN, Feldmann M, et al. Randomized doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  67. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNF monoclonal antibody (Mab) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of a double-blind, placebo controlled multicenter trial (abstract). Arthritis Rheum 1996; 39: S123

    Article  Google Scholar 

  68. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 41: 1552–63

    Article  Google Scholar 

  69. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42

    Article  PubMed  CAS  Google Scholar 

  70. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF Carriers and TNF antagonists. J Immunol 1993; 151: 1548–61

    PubMed  CAS  Google Scholar 

  71. Nam MH, Reda D, Boujouko S, et al. Recombinant human chimeric tumor necrosis factor (TNF) receptor (TNFR: Fc): Safety and pharmacokinetics in humans (abstract). Clin Res 1993; 41

  72. Moreland LW, Margolies GR, Heck LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849–55

    PubMed  CAS  Google Scholar 

  73. Hochberg MC, Chang RW, Dwosh I, et al. American College of Rheumatology, 1991, revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502

    Article  PubMed  CAS  Google Scholar 

  74. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337: 141–7

    Article  CAS  Google Scholar 

  75. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised controlled trial. Ann Intern Med. In press

  76. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9

    Google Scholar 

  77. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729–40

    Article  PubMed  CAS  Google Scholar 

  78. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant huan tumour necrosis factor receptor (p75)-c fusion protein. N Engl J Med 1997; 337: 141–7

    Article  PubMed  CAS  Google Scholar 

  79. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61: 224–8

    Article  PubMed  CAS  Google Scholar 

  80. Beutler B, van Huffel C. Unravelling function in the TNF ligand and receptor families. Science 1994; 264: 667–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arthritis Clinical Intervention Program, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA

    Larry W. Moreland

  2. Division of Clinical Immunology and Rheumatology, 1717 6th Avenue South, Room 068, Birmingham, AL, 35294-7201, USA

    Larry W. Moreland

Authors
  1. Larry W. Moreland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry W. Moreland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreland, L.W. Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis. BioDrugs 11, 201–210 (1999). https://doi.org/10.2165/00063030-199911030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911030-00006

Keywords

Search

Navigation